Pharma & Biotech Patent Litigation in Amsterdam

Pharma and Biotech patent law continues to evolve rapidly, perhaps faster than patent law in any other field, with numerous significant case law developments arising from new tactics being employed by generics in recent times. Given the highly competitive and lucrative nature of the industry, it is more important than ever that patent/IP departments and patent attorneys stay abreast of recent court decisions on a global level, as well as current litigation tactics, to ensure they are implementing the most competitive strategies to protect and defend their patent portfolios and maximise revenues on inventions.

The 2012 Pharma & Biotech Patent Litigation forum will focus on the latest case law developments on pharma and biotech patents across Europe and the US and how decisions in the various national courts will inevitably impact on the litigation strategies you employ. You will walk away with fresh insights, tactics and tools to strategise your litigation techniques and remain competitive in today’s constantly changing patent landscape.

C5’s 4th Annual Forum on Pharma & Biotech Patent Litigation brings together key regulators and judicial authorities, distinguished in-house counsel from the world’s largest pharma and biotech companies, and their expert legal advisors from across Europe and the US. Based on their first-hand experience in recent pharma and biotech patent litigation, the expert panel will provide you with important case law updates and invaluable strategies to combat the latest challenges.

Key issues to be addressed include:

• The enforceability of gene sequence patents in light of HGS v Lilly
• SPC references and recent opinion by the Advocate General: what you need to know to file your SPC applications
• EPO update on pharma and biotech patent litigation in Europe
• The interplay between insufficiency of disclosure and future embodiments in biotech inventions
• The significance of case law developments across Eastern Europe and what they mean for your patent litigation strategies
• The impact of recent launch strategies by generics on evolving preliminary and interim injunctions across Europe
• Developing a successful strategy for pan-European patent enforcement following recent case law developments on cross-border injunctions
• Recent US developments in pharma and biotech patent litigation
• How should you instruct scientific experts in your patent litigation proceedings in light of recent case law?
• The stem cell patent landscape: overcoming the commercial obstacles
• Commercial strategies to combat recent cross-border detention challenges
• Capitalising on research tool patents: scope and enforcement
• Disclosure of prior art and antitrust issues in the settlement of pharma patent disputes
• Second medical use claims: back in the spotlight

For more information please visit this website: www.c5-online.com/2012/653/pharma--biotech-patent-litigation

BIO Deutschland members get a discount of 20 %.